Astex Pharmaceuticals, Inc. Message Board
-
great pipeline
-
news is coming
-
CLDX should pop tomorrow. Catalysts are coming. I won't elaborate further since I have posted what they are before.
-
Celldex is the plase to be:
Coming catalysts include hiv trial results, start of cdx-011 phase 3, start of cdx-1407 and dacogen for leukemia and many others. $25 could occur this yr. -
Stock could soar when AM speaks next week.
Coming catalysts include hiv trial results, start of cdx-011 phase 3, start of cdx-1407 and dacogen for leukemia and many others. $25 could occur this yr. -
Coming catalysts include hiv trial results, start of cdx-011 phase 3, start of cdx-1407 and dacogen for leukemia and many others. $25 could occur this yr.
- Reply to
Is the embargoed Avastin abstract re: phase-3 trial in GBM the most important for CLDX?
by lovethe90s •19 hours agoSorry, meant cdx-1401
This phase I trial studies the side effects and immune response to DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in ... Adult Acute Myeloid Leukemia - Reply to
Is the embargoed Avastin abstract re: phase-3 trial in GBM the most important for CLDX?
by lovethe90s •19 hours agoOther catalysts are when the hiv trial results come out, start of cdx-011 phase 3, start of cdx-1407 and dacogen for leukemia.......
-
It is great that we are one day closer to the start of phase 3. Little else matters.
-
Great pipeline
-
I bet Whip is loading up with cldx today.
-
Yes. Horrific gains are coming. We are now one day closer to start of cdx-011 phase 3, hiv trial results, start of cdx-1401 in leukemia and many other goodies.
-
And this could be a major topic!
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
This study is not yet open for participant recruitment.
Verified May 2013 by Roswell Park Cancer Institute
Sponsor:
Roswell Park Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer InstituteClinicalTrials.gov Identifier:
NCT01834248
First received: April 12, 2013
Last updated: May 7, 2013
Last verified: May 2013
History of Changes -
I believe good times are ahead.
-
Phase 3 drug will start this yr.
-
The market for acute myeloid leukemia therapeutics market in the G8 countries (USA, Canada, UK, Germany, Italy, France, Spain and Japan) was valued at $216 million in 2010 and is expected to grow at a CAGR of 28.40% from 2015 to 2020, to reach a value of $1.67 billion, according to a new report added to the offering of Markets and Markets.
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia -
drrr, it does not matter. Lots of companies that are presenting have had no run up. The big news that people are not talking about is the following:
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia -
I know they will have a booth there. I am not sure if they are presenting there this year. Don't let that phase you. CLDX is up hundreds of percent in the last 18 months. The big event will be when they start phase 3 for cdx-011. There is bigger than normal after hours trading today and most trades are higher than the closing price. imo, something big is going to happen.
-
Before their phase 3 starts!
-
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
This study is not yet open for participant recruitment.
Verified May 2013 by Roswell Park Cancer Institute
Sponsor:
Roswell Park Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute
Don't you understand. CDX-1401 is starting a novel trial soon and Celldex is not paying for it.
Also, ASCO, HIV trial results, start of cdx-011 phase 3, etc. Be careful selling too early